Cleartronic, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cleartronic, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.10M | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | $3.13M | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $2.13M | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $2.02M | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $1.65M | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $1.75M | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | $1.16M | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | $782.2K | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $346.9K | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | $544.8K | Jan 16, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.21M | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | $2.26M | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $1.70M | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $1.68M | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $1.38M | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $1.34M | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | $918.1K | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | $658.6K | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $263.4K | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | $365.0K | Jan 16, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($154.2K) | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | ($272.1K) | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $56.6K | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $400.9K | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $361.1K | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $165.3K | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | ($176.6K) | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | ($532.8K) | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | ($859.2K) | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | ($574.3K) | Jan 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | ($851.0K) | Jan 16, 2018 |
| FY2017 | Sep 30, 2016 | ($460.1K) | Jan 16, 2018 |
| FY2016 | Sep 30, 2015 | ($1.47M) | Jan 13, 2017 |
| FY2015 | Sep 30, 2014 | ($224.9K) | Jan 13, 2016 |
| FY2014 | Sep 30, 2013 | ($1.93M) | Jan 13, 2015 |
| FY2013 | Sep 30, 2012 | ($921.8K) | Jan 14, 2014 |
| FY2012 | Sep 30, 2011 | ($1.20M) | Jan 17, 2013 |
| FY2011 | Sep 30, 2010 | ($1.09M) | Dec 30, 2011 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.0K | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | $189.0K | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $27.3K | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $19.7K | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $167.7K | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $152.6K | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | $207.7K | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | $222.3K | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $105.8K | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | $14.6K | Jan 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $284.1K | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | $414.9K | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $99.6K | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $74.6K | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $378.6K | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | ($1.8K) | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | ($69.4K) | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | ($21.4K) | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | ($259.0K) | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | ($49.1K) | Jan 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $32.1K | Mar 21, 2025 |
| FY2024 | Sep 30, 2023 | $6.4K | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $7.5K | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $5.1K | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $9.0K | Dec 29, 2021 |
| FY2011 | Sep 30, 2010 | $4.0K | Dec 30, 2011 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.61M | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | $1.30M | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $1.30M | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $1.15M | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $839.5K | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $393.3K | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | $302.2K | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | $217.6K | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $369.7K | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | $301.8K | Jan 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.96M | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | $1.50M | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $1.29M | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $1.20M | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $1.29M | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $1.18M | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | $1.48M | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | $1.41M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | $1.03M | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | $653.0K | Jan 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($356.7K) | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | ($202.4K) | Dec 30, 2025 |
| FY2025 | Sep 30, 2023 | $5.2K | Dec 30, 2025 |
| FY2024 | Sep 30, 2022 | ($51.4K) | Mar 21, 2025 |
| FY2023 | Sep 30, 2021 | ($452.3K) | Dec 21, 2023 |
| FY2021 | Sep 30, 2020 | ($786.8K) | Dec 29, 2021 |
| FY2021 | Sep 30, 2019 | ($1.18M) | Dec 29, 2021 |
| FY2020 | Sep 30, 2018 | ($1.19M) | Feb 18, 2021 |
| FY2019 | Sep 30, 2017 | ($655.3K) | Jan 14, 2020 |
| FY2018 | Sep 30, 2016 | ($351.2K) | Jan 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($15.60M) | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | ($15.44M) | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | ($15.24M) | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | ($15.29M) | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | ($15.69M) | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | ($16.06M) | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | ($16.22M) | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | ($16.04M) | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | ($15.51M) | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | ($14.65M) | Jan 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.12M | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | $849.7K | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | $517.0K | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | $468.2K | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | $401.0K | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $76.0K | Dec 29, 2021 |
| FY2021 | Sep 30, 2019 | $27.7K | Dec 29, 2021 |
| FY2020 | Sep 30, 2018 | $413 | Feb 18, 2021 |
| FY2019 | Sep 30, 2017 | $7.6K | Jan 14, 2020 |
| FY2018 | Sep 30, 2016 | $2.6K | Jan 22, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Dec 21, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | 0 | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | 0 | Jan 22, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | 0 | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | 0 | Dec 29, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 229.24M | Dec 30, 2025 |
| FY2025 | Sep 30, 2024 | 229.16M | Dec 30, 2025 |
| FY2024 | Sep 30, 2023 | 229.16M | Mar 21, 2025 |
| FY2023 | Sep 30, 2022 | 229.16M | Dec 21, 2023 |
| FY2021 | Sep 30, 2021 | 228.58M | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | 223.99M | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | 211.99M | Feb 18, 2021 |
| FY2019 | Sep 30, 2018 | 203.90M | Jan 14, 2020 |
| FY2018 | Sep 30, 2017 | 203.90M | Jan 22, 2019 |
| FY2017 | Sep 30, 2016 | 203.90M | Jan 16, 2018 |